PRPH (ProPhase Labs) ROC %: -30.80% (As of Dec. 2025)

What is ProPhase Labs ROC %?

ProPhase Labs PRPH -4.61% ROC % is -30.80% as of Dec. 2025. The stock has 4 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. ProPhase Labs's annualized return on capital (ROC %) for the quarter that ended in Dec. 2025 was -30.80%.

As of today (2026-06-26), ProPhase Labs's WACC % is 52.06%. ProPhase Labs's ROC % is -36.77% (calculated using TTM income statement data). ProPhase Labs earns returns that do not match up to its cost of capital. It will destroy value as it grows.

ProPhase Labs (OTCPK:PRPH) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, ProPhase Labs's WACC % is 52.06%. ProPhase Labs's ROC % is -36.77% (calculated using TTM income statement data). ProPhase Labs earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

ProPhase Labs ROC % Related Terms

ProPhase Labs ROC % Historical Data

* Premium members only.

The historical data trend for ProPhase Labs's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProPhase Labs ROC % Chart

ProPhase Labs Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROC %

Get a 7-Day Free Trial

25.64

32.72

-23.81

-64.34

-31.96

ProPhase Labs Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
ROC %	Get a 7-Day Free Trial															-115.16	-35.85	-50.65	-38.26	-30.80

ProPhase Labs ROC % Calculation

ProPhase Labs's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2025 is calculated as:

	ROC % (A: Dec. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Dec. 2024 )	+	Invested Capital (A: Dec. 2025 ))	/ count )
=	-18.047 * ( 1 - 0% )	/	( (46.696	+	66.251)	/ 2 )
=	-18.047	/	56.4735
=	-31.96 %

where

	Invested Capital		(A: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	63.2	-	18.001	-	( 0.678	-	max(0, 32.134	-	30.637	+	0.678	))
=	46.696

	Invested Capital		(A: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	59.871	-	43.551	-	( 0.09	-	max(0, 53.081	-	3.15	+	0.09	))
=	66.251

ProPhase Labs's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2025 is calculated as:

	ROC % (Q: Dec. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2025 )	+	Invested Capital (Q: Dec. 2025 ))	/ count )
=	-22.904 * ( 1 - 7.76% )	/	( (70.926	+	66.251)	/ 2 )
=	-21.1266496	/	68.5885
=	-30.80 %

where

	Invested Capital		(Q: Sep. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	65.702	-	42.29	-	( 0.405	-	max(0, 55.287	-	7.773	+	0.405	))
=	70.926

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	59.871	-	43.551	-	( 0.09	-	max(0, 53.081	-	3.15	+	0.09	))
=	66.251

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data. The tax rate is limited to between 0% and 100%.

Frequently Asked Questions Learn more about ROC % →

What does a ROC % of -30.80% mean?

ProPhase Labs (PRPH) has a ROC % of -30.80% as of Dec. 2025. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on ProPhase Labs and its competitors.

Is ProPhase Labs' ROC % too high?

ProPhase Labs' current ROC % is -30.80%.

How does ProPhase Labs' ROC % compare to NSTM and IDTA?

ProPhase Labs' ROC % of -30.80% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROC % for a Medical Diagnostics & Research company?

A good ROC % depends on the Medical Diagnostics & Research industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROC % mean?

A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on ProPhase Labs and its competitors. ProPhase Labs's current ROC % is -30.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is ProPhase Labs stock overvalued right now?

Based on GuruFocus' analysis, ProPhase Labs (PRPH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.65, compared to a current price of $0.09 — trading 86% below its estimated fair value. The current ROC % is -30.80%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROC % calculated?

ROC % is calculated from a company's financial statements. For ProPhase Labs (PRPH), the current ROC % is -30.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ProPhase Labs Business Description

Industry Healthcare Medical Diagnostics & Research

Comparable Companies NSTM IDTA IVRO FUNI TMO DHR SHSE:603259 XSWX:LONN IDXX A WAT NTRA IQV ILMN MTD DGX LH GH MEDP XPAR:ERF

Address 626 RXR Plaza, 6th Floor, Uniondale, NY, USA, 11556

Website https://www.prophaselabs.com

ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.